RAC3: A Protein Involved in Disease and Therapeutic Approaches

Target Name: RAC3

NCBI ID: G5881

RAC3

RAC3: A Protein Involved in Disease and Therapeutic Approaches

Ras-related C3 botulinum toxin substrate 3 (RAC3) is a protein that is expressed in various tissues throughout the body, including the nervous system, endocrine system, and muscular system. It is a key regulator of muscle contractions and is involved in the development and maintenance of muscle strength and function. In recent years, scientists have identified RAC3 as a potential drug target or biomarker, which could lead to new therapeutic approaches for various diseases.

Diseases and Therapies

RAC3 has been linked to a number of diseases and therapies. In the context of muscular system disorders, RAC3 has been shown to play a role in the pathogenesis of various muscle disorders, including dystrophy, myopathies, and neurodegenerative diseases. For example, studies have shown that overexpression of RAC3 can contribute to the development of dystrophy in mice, and that inhibition of RAC3 can protect against the progression of neurodegenerative diseases in dogs.

In the context of cancer, RAC3 has been shown to be involved in the development and progression of various types of cancer, including breast, lung, and colorectal cancers. For example, research has shown that RAC3 can be expressed in various types of cancer and that overexpression of RAC3 can promote the growth and metastasis of cancer cells. inhibition of RAC3 has been shown to be a potential therapeutic approach for cancer treatment.

Drugs and Treatments

Several drugs have been shown to target RAC3 and have been used in clinical trials to treat various diseases. One of the most promising drugs is a small molecule inhibitor of RAC3, called RAC3 inhibitor, which has been shown to protect against the development of neurodegenerative diseases in dystrophied mice. The drug has also been shown to improve muscle strength and function in dystrophied mice.

Another drug that targets RAC3 is a monoclonal antibody (mAb) called RAC3 antibody, which has been shown to reduce the production of collagen in wound-induced myofibrosis in rats. The mAb has also been shown to protect against the development of neurodegenerative diseases in dystrophied mice.

Conclusion

RAC3 is a protein that is expressed in various tissues throughout the body and is involved in the development and maintenance of muscle strength and function. It has been linked to a number of diseases, including muscular system disorders and cancer. Several drugs, including RAC3 inhibitor and RAC3 antibody, have been shown to target RAC3 and have been used in clinical trials to treat various diseases. Further research is needed to fully understand the role of RAC3 in disease and to develop new therapeutic approaches.

Protein Name: Rac Family Small GTPase 3

Functions: Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as cell spreading and the formation of actin-based protusions including lamellipodia and membrane ruffles. Promotes cell adhesion and spreading on fibrinogen in a CIB1 and alpha-IIb/beta3 integrin-mediated manner

The "RAC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets